To earn CME related to this news article, click here. April 20, 2009 — A single 5-mg intravenous infusion of zoledronic acid was at least as effective and more acceptable to patients than 5 mg of oral ...

Please provide your email address to receive an email when new articles are posted on . Administering a once-yearly infusion of zoledronic acid within 90 days after the surgical repair of a low-trauma ...

Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...

Novartis launches ready-to-use formulation of Zometa (zoledronic acid), a bone targeted agent for skeletal complications in advanced cancers and multiple myeloma Novartis launches ready-to-use ...

Paracetamol taken for 3 days reduces post-dose symptoms related to zoledronic acid infusion, new research reveals. Transient post-dose symptoms, including fever and myalgia, may occur following the ...

The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...

Imagine going to the doctor’s office once a year for treatment of a chronic medical condition. No daily pills. No weekly therapies. Just 30 minutes or so in a clinic. It could happen. A new ...

SAN ANTONIO (AP) - One of the most promising new approaches for fighting breast cancer took a stunning setback Thursday when a major study showed that a bone-building drug did not stop cancer from ...

September 1, 2011 — Zoledronic acid (Reclast, Novartis Pharmaceuticals), an injectable bisphosphonate used to prevent and treat osteoporosis, is now contraindicated for patients with creatinine ...

The serendipitous result of a clinical trial shows that a drug given to breast cancer patients to maintain their bone density actually increased their survival rate. Seven years after the initial ...

SAN ANTONIO – One of the most promising new approaches for fighting breast cancer took a stunning setback Thursday when a major study showed that a bone-building drug did not stop cancer from ...